X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13551) 13551
Book Review (2508) 2508
Publication (535) 535
Newspaper Article (367) 367
Newsletter (279) 279
Magazine Article (84) 84
Book Chapter (67) 67
Conference Proceeding (63) 63
Trade Publication Article (26) 26
Web Resource (20) 20
Book / eBook (13) 13
Dissertation (11) 11
Reference (4) 4
Data Set (3) 3
Paper (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11012) 11012
humans (9495) 9495
diuretics (6238) 6238
male (5993) 5993
female (4999) 4999
middle aged (3569) 3569
diuretics - therapeutic use (3495) 3495
aged (3097) 3097
diuretics - administration & dosage (2928) 2928
adult (2687) 2687
animals (2542) 2542
hypertension - drug therapy (2505) 2505
hypertension (2114) 2114
abridged index medicus (1908) 1908
diuretics - pharmacology (1824) 1824
drug therapy, combination (1683) 1683
pharmacology & pharmacy (1669) 1669
heart failure (1507) 1507
rats (1425) 1425
blood pressure - drug effects (1410) 1410
cardiac & cardiovascular systems (1320) 1320
treatment outcome (1309) 1309
heart failure - drug therapy (1295) 1295
furosemide (1218) 1218
diuretics - adverse effects (1186) 1186
antihypertensive agents - therapeutic use (1150) 1150
blood pressure (1043) 1043
risk factors (1043) 1043
drug therapy (1042) 1042
mortality (997) 997
furosemide - administration & dosage (984) 984
time factors (980) 980
antihypertensive agents - administration & dosage (924) 924
dose-response relationship, drug (915) 915
medicine, general & internal (907) 907
care and treatment (815) 815
aged, 80 and over (808) 808
analysis (796) 796
research (766) 766
angiotensin-converting enzyme inhibitors - therapeutic use (765) 765
hypertension - physiopathology (732) 732
furosemide - pharmacology (731) 731
dosage and administration (717) 717
medicine & public health (709) 709
double-blind method (708) 708
peripheral vascular disease (688) 688
urology & nephrology (655) 655
furosemide - therapeutic use (645) 645
health aspects (645) 645
hydrochlorothiazide (633) 633
therapy (622) 622
adrenergic beta-antagonists - therapeutic use (618) 618
administration, oral (605) 605
adolescent (599) 599
patients (596) 596
prospective studies (591) 591
blood-pressure (582) 582
kidney - drug effects (570) 570
heart failure - physiopathology (559) 559
retrospective studies (543) 543
management (542) 542
clinical trials as topic (535) 535
benzothiadiazines (523) 523
urine (520) 520
sodium (510) 510
internal medicine (490) 490
follow-up studies (487) 487
hydrochlorothiazide - administration & dosage (486) 486
drugs (485) 485
cardiology (484) 484
angiotensin-converting enzyme inhibitors - administration & dosage (483) 483
risk (476) 476
diuresis - drug effects (475) 475
hypertension - complications (460) 460
antihypertensive agents - adverse effects (449) 449
sodium chloride symporter inhibitors - therapeutic use (444) 444
diuretic (435) 435
prognosis (425) 425
potassium (424) 424
hydrochlorothiazide - therapeutic use (423) 423
sodium - urine (420) 420
calcium channel blockers - therapeutic use (415) 415
child (412) 412
medical research (408) 408
diagnosis (406) 406
physiology (406) 406
pediatrics (400) 400
infusions, intravenous (397) 397
old medline (396) 396
clinical trials (392) 392
diuresis (384) 384
sodium chloride symporter inhibitors - administration & dosage (382) 382
potassium - blood (380) 380
acute disease (379) 379
dogs (378) 378
studies (378) 378
drug combinations (376) 376
drug interactions (376) 376
drug administration schedule (373) 373
rats, sprague-dawley (372) 372
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12903) 12903
German (390) 390
French (228) 228
Russian (210) 210
Japanese (173) 173
Italian (102) 102
Spanish (94) 94
Norwegian (37) 37
Portuguese (33) 33
Polish (32) 32
Danish (31) 31
Swedish (27) 27
Chinese (25) 25
Czech (17) 17
Dutch (17) 17
Hungarian (15) 15
Romanian (10) 10
Korean (8) 8
Lithuanian (8) 8
Bulgarian (5) 5
Finnish (5) 5
Hebrew (4) 4
Serbian (4) 4
Turkish (4) 4
Slovak (3) 3
Ukrainian (3) 3
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Index Medicus | Abridged Index Medicus | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
Annals of Surgery, ISSN 0003-4932, 08/2013, Volume 258, Issue 2, pp. 262 - 269
OBJECTIVE:We conducted a pharmacokinetic (PK) study and a pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated... 
furosemide | oral cocktail | CYP3A | gastric bypass | drug metabolism | SURGERY | FATTY LIVER-DISEASE | WEIGHT-LOSS | TRENDS | P-GLYCOPROTEIN | OBESITY | INTESTINAL ADAPTATION | BARIATRIC SURGERY | ABSORPTION | HEPATIC STEATOSIS | Gastric Bypass | Diuretics - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Middle Aged | Tolbutamide - urine | Male | Caffeine - pharmacokinetics | Midazolam - urine | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Diuretics - urine | Diuretics - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Furosemide - pharmacokinetics | Omeprazole - administration & dosage | Excitatory Amino Acid Antagonists - administration & dosage | Hypoglycemic Agents - urine | Omeprazole - urine | Central Nervous System Stimulants - pharmacokinetics | Midazolam - blood | Dextromethorphan - urine | Adolescent | GABA Modulators - urine | Central Nervous System Stimulants - urine | Dextromethorphan - administration & dosage | Furosemide - administration & dosage | Tolbutamide - administration & dosage | Tolbutamide - pharmacokinetics | Caffeine - administration & dosage | Omeprazole - blood | GABA Modulators - pharmacokinetics | Midazolam - administration & dosage | Anti-Ulcer Agents - blood | Chromatography, High Pressure Liquid | Case-Control Studies | Excitatory Amino Acid Antagonists - urine | Hypoglycemic Agents - blood | Tandem Mass Spectrometry | Biotransformation | Adult | Female | Dextromethorphan - pharmacokinetics | Furosemide - urine | Caffeine - urine | Caffeine - blood | GABA Modulators - administration & dosage | GABA Modulators - blood | Omeprazole - pharmacokinetics | Anti-Ulcer Agents - urine | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Dextromethorphan - blood | Excitatory Amino Acid Antagonists - blood | Tolbutamide - blood | Aged | Central Nervous System Stimulants - blood | Pharmacokinetics | Central Nervous System Stimulants - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
by Caraceni, Paolo and Riggio, Oliviero and Angeli, Paolo and Alessandria, Carlo and Neri, Sergio and Neri, Elga and Foschi, Francesco G and Levantesi, Fabio and Airoldi, Aldo and Boccia, Sergio and Svegliati-Baroni, Gianluca and Fagiuoli, Stefano and Romanelli, Roberto G and Cozzolongo, Raffaele and Di Marco, Vito and Sangiovanni, Vincenzo and Morisco, Filomena and Toniutto, Pierluigi and Tortora, Annalisa and De Marco, Rosanna and Angelico, Mario and Cacciola, Irene and Elia, Chiara and Elia, Gianfranco and Federico, Alessandro and Massironi, Sara and Guarisco, Riccardo and Galioto, Alessandra and Ballardini, Giorgio and Rendina, Maria and Nardelli, Silvia and Piano, Salvatore and Prestianni, Loredana and Cappa, Federica Mirici and Cesarini, Lucia and Simone, Loredana and Pasquale, Chiara and Cavallin, Marta and Andrealli, Alida and Fidone, Federica and Ruggeri, Matteo and Roncadori, Andrea and Baldassarre, Maurizio and Tufoni, Manuel and Zaccherini, Giacomo and Bernardi, Mauro and Domenicali, Marco and Giannone, Ferdinando A and Merli, Manuela and Gioia, Stefania and Fasolato, Silvano and Sticca, Antonietta and Campion, Daniela and Risso, Alessandro and Saracco, Giorgio M and Maiorca, Daniela and Rizzotto, Agostino and Lanzi, Arianna and Visani, Anna and Mastroianni, Antonio and Alberti, Alberto B and Mazzarelli, Chiara and Vangeli, Marcello and Marzioni, Marco and Capretti, Francesca and Kostandini, Alba and Magini, Giulia and Colpani, Maria and Laffi, Giacomo and Gabbani, Tommaso and Marsico, Maria and Zappimbulso, Marianna and Petruzzi, Josè and Calvaruso, Vincenza and Parrella, Giovanni and Caporaso, Nicola and Auriemma, Francesco and Guarino, Maria and Pugliese, Fabio and Gasbarrini, Antonio and Leo, Pietro and De Leonardis, Francesco and Pecchioli, Alessandra and Rossi, Piera and Raimondo, Giovanni and Negri, Elisa and Dallio, Marcello and Loguercio, Carmelina and Conte, Dario and Celli, Natascia and Bringiotti, Roberto and Castellaneta, Nicola M and Salerno, Francesco and ANSWER Study Investigators
The Lancet, ISSN 0140-6736, 06/2018, Volume 391, Issue 10138, pp. 2417 - 2429
Journal Article
BMC Nephrology, ISSN 1471-2369, 10/2015, Volume 16, Issue 1, pp. 158 - 158
Background: Dose adjustment for certain drugs is required in patients with reduced renal function to avoid toxicity as many drugs are eliminated by the... 
Prospective | Dose adjustment | Renal impairment | DOSING ADJUSTMENTS | ERRORS | DIET | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | Prospective Studies | Spironolactone - administration & dosage | Humans | Middle Aged | Fluconazole - administration & dosage | Antihypertensive Agents - administration & dosage | Male | Young Adult | Drug Dosage Calculations | Aged, 80 and over | Adult | Female | Cimetidine - administration & dosage | Enalapril - administration & dosage | Pharmaceutical Preparations - administration & dosage | Medication Errors | Severity of Illness Index | Diuretics - administration & dosage | Vancomycin - administration & dosage | Cross-Sectional Studies | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Hospitalization | Acute Kidney Injury - physiopathology | Anti-Arrhythmia Agents - administration & dosage | Creatinine - urine | Renal Insufficiency, Chronic - physiopathology | Anti-Ulcer Agents - administration & dosage | Gout Suppressants - administration & dosage | Drug Prescriptions - statistics & numerical data | Allopurinol - administration & dosage | Digoxin - administration & dosage | Adolescent | Ceftazidime - administration & dosage | Creatinine - blood | Aged | Anti-Bacterial Agents - administration & dosage | Antifungal Agents - administration & dosage | Ethiopia | Drugs | Prescribing | Medical research | Hospital patients | Prescription writing | Analysis | Medicine, Experimental | Medical care | Quality management | Index Medicus
Journal Article
Journal of Nephrology, ISSN 1121-8428, 12/2014, Volume 27, Issue 6, pp. 659 - 666
The novel iron-based phosphate binder sucroferric oxyhydroxide is being investigated for the treatment of hyperphosphatemia. Patients with chronic kidney... 
Nephrology | Phase I | Medicine & Public Health | Urology/Andrology | Hyperphosphatemia | Chronic kidney disease | Pharmacokinetics | Sucroferric oxyhydroxide | MORTALITY | PHOSPHORUS | PHOSPHATE BINDER | BIOAVAILABILITY | INDIVIDUALS | DIALYSIS PATIENTS | PA21 | CALCIUM | UROLOGY & NEPHROLOGY | HEMODIALYSIS | CHRONIC KIDNEY-DISEASE | Digoxin - adverse effects | Diuretics - pharmacokinetics | Chelating Agents - administration & dosage | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Warfarin - administration & dosage | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Cardiotonic Agents - adverse effects | Diuretics - blood | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Risk Assessment | Furosemide - pharmacokinetics | Cardiotonic Agents - pharmacokinetics | Omeprazole - administration & dosage | Sucrose - adverse effects | Anticoagulants - adverse effects | Anticoagulants - blood | Cardiotonic Agents - administration & dosage | Models, Biological | Ferric Compounds - adverse effects | Losartan - administration & dosage | Diuretics - adverse effects | Furosemide - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Anticoagulants - administration & dosage | Area Under Curve | Losartan - blood | Omeprazole - blood | Warfarin - adverse effects | Ferric Compounds - administration & dosage | Healthy Volunteers | Furosemide - adverse effects | Adult | Female | Proton Pump Inhibitors - blood | Digoxin - blood | Losartan - pharmacokinetics | Chelating Agents - adverse effects | Furosemide - blood | Sucrose - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Models, Statistical | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Proton Pump Inhibitors - pharmacokinetics | Digoxin - administration & dosage | Cardiotonic Agents - blood | Warfarin - blood | Losartan - adverse effects | Anticoagulants - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - blood | Drug Combinations | Index Medicus | Original
Journal Article
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 11/2015, Volume 4, Issue 6, pp. 407 - 417
LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor in development for treatments of hypertension and heart failure indications. In 3 separate... 
LCZ696 | pharmacokinetic drug–drug interaction | amlodipine | hydrochlorothiazide | carvedilol | Pharmacokinetic drug-drug interaction | Amlodipine | Hydrochlorothiazide | Carvedilol | STEADY-STATE PHARMACOKINETICS | ANTAGONIST | NATRIURETIC PEPTIDES | pharmacokinetic drug-drug interaction | HEART-FAILURE | EXCRETION | PHARMACOLOGY & PHARMACY | DYSFUNCTION | VALSARTAN | Hydrochlorothiazide - pharmacokinetics | Diuretics - pharmacokinetics | Humans | Middle Aged | Male | Metabolic Clearance Rate | Tetrazoles - blood | Adrenergic beta-Antagonists - pharmacokinetics | Drug Interactions | Tetrazoles - administration & dosage | Adrenergic beta-Antagonists - adverse effects | Amlodipine - administration & dosage | Arizona | Diuretics - blood | Hydrochlorothiazide - adverse effects | Diuretics - administration & dosage | Administration, Oral | Amlodipine - adverse effects | Propanolamines - adverse effects | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Models, Biological | Calcium Channel Blockers - administration & dosage | Protease Inhibitors - blood | Calcium Channel Blockers - blood | Propanolamines - administration & dosage | Diuretics - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin Receptor Antagonists - adverse effects | Angiotensin Receptor Antagonists - pharmacokinetics | Calcium Channel Blockers - adverse effects | Area Under Curve | Protease Inhibitors - pharmacokinetics | Carbazoles - administration & dosage | Aminobutyrates - adverse effects | Antihypertensive Agents - administration & dosage | Healthy Volunteers | Propanolamines - pharmacokinetics | Amlodipine - pharmacokinetics | Aminobutyrates - pharmacokinetics | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Carbazoles - blood | Aminobutyrates - administration & dosage | Drug Therapy, Combination | Propanolamines - blood | Hydrochlorothiazide - blood | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - blood | Carbazoles - adverse effects | Amlodipine - blood | Drug Administration Schedule | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Neprilysin - metabolism | Aminobutyrates - blood | Angiotensin Receptor Antagonists - blood | Carbazoles - pharmacokinetics | Neprilysin - antagonists & inhibitors | Tetrazoles - adverse effects | Calcium Channel Blockers - pharmacokinetics | Angiotensin Receptor Antagonists - administration & dosage | Prescription drugs | Beta blockers | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 9, pp. 797 - 805
Journal Article